Search Results - "Castillo, Oleguer"

Determinants of activity and efficacy of anti-PD1/PD-L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective biomarker-based study by García-Corbacho, Javier, Indacochea, Alberto, González Navarro, Azucena E., Victoria, Iván, Moreno, Débora, Pesántez, David, Angelats, Laura, Modrego-Sanchez, Andrea, Sanfeliu, Esther, Castillo, Oleguer, Blasco, Paula, Mezquita, Laura, Viñolas, Nuria, Nogué, Miquel, Galván, Patricia, Adamo, Barbara, Basté, Neus, Sauri, Tamara, Juan, Manel, Prat, Aleix, Schettini, Francesco

“…Immune-checkpoint inhibitors (ICI) have revolutionized the therapeutic landscape of cancer. However, optimal patient selection is still an unmet need…”
Get full text

Comparative biological activity of palbociclib and ribociclib in hormone receptor-positive breast cancer by Lorman-Carbó, Natàlia, Martínez-Sáez, Olga, Fernandez-Martinez, Aranzazu, Galván, Patricia, Chic, Nuria, Garcia-Fructuoso, Isabel, Rodríguez, Adela, Gómez-Bravo, Raquel, Schettini, Francesco, Blasco, Paula, Castillo, Oleguer, González-Farré, Blanca, Adamo, Barbara, Vidal, Maria, Muñoz, Montserrat, Perou, Charles M., Malumbres, Marcos, Gavilá, Joaquín, Pascual, Tomás, Prat, Aleix, Brasó-Maristany, Fara

“…This study examines the biological effects of palbociclib and ribociclib in hormone receptor-positive breast cancer, pivotal to the HARMONIA prospective phase…”
Get full text

Correction to: Determinants of activity and efficacy of anti-PD1/PD-L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective biomarker-based study by García-Corbacho, Javier, Indacochea, Alberto, González Navarro, Azucena E., Victoria, Iván, Moreno, Débora, Pesántez, David, Angelats, Laura, Modrego-Sanchez, Andrea, Sanfeliu, Esther, Castillo, Oleguer, Blasco, Paula, Mezquita, Laura, Viñolas, Nuria, Nogué, Miquel, Galván, Patricia, Adamo, Barbara, Basté, Neus, Sauri, Tamara, Juan, Manel, Prat, Aleix, Schettini, Francesco

Get full text

HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial by Guarneri, Valentina, Brasó-Maristany, Fara, Dieci, Maria Vittoria, Griguolo, Gaia, Paré, Laia, Marín-Aguilera, Mercedes, Miglietta, Federica, Bottosso, Michele, Giorgi, Carlo Alberto, Blasco, Paula, Castillo, Oleguer, Galván, Patricia, Vivancos, Ana, Villagrasa, Patricia, Parker, Joel S., Perou, Charles M., Conte, PierFranco, Prat, Aleix

“…HER2DX is a prognostic and predictive assay in early-stage HER2-positive breast cancer based on clinical features and the expression of 4 gene signatures…”
Get full text

Assessment of the HER2DX Assay in Patients With ERBB2-Positive Breast Cancer Treated With Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab by Waks, Adrienne G, Ogayo, Esther R, Paré, Laia, Marín-Aguilera, Mercedes, Brasó-Maristany, Fara, Galván, Patricia, Castillo, Oleguer, Martínez-Sáez, Olga, Vivancos, Ana, Villagrasa, Patricia, Villacampa, Guillermo, Tarantino, Paolo, Desai, Neelam, Guerriero, Jennifer, Metzger, Otto, Tung, Nadine M, Krop, Ian E, Parker, Joel S, Perou, Charles M, Prat, Aleix, Winer, Eric P, Tolaney, Sara M, Mittendorf, Elizabeth A

“…Patients with early-stage ERBB2 (formerly HER2)-positive breast cancer (ERBB2+ BC) who experience a pathologic complete response (pCR) after receiving…”
Get more information

Abstract PO1-06-02: Solti-1716 TATEN phase II trial: Targeting non-Luminal disease by PAM50 with pembrolizumab and paclitaxel in Hormone Receptor-positive/HER2-negative advanced breast cancer (ABC) by Prat, Aleix, Conte, Benedetta, Brasó-Maristany, Fara, Chic, Nuria, Muñoz, Montserrat, Hernando, Cristina, Alva, Manuel, Vazquez, Silvia, Blanch, Salvador, Oliveira, Mafalda, Fernández, Esther, Castillo, Oleguer, Galván, Patricia, Aguirre, Ángela, Sanfeliu, Esther, Villanueva, Lorea, Pascual, Tomás, Ciruelos, Eva

“…Background Within HR+/HER2-negative breast cancer, PAM50 non-luminal tumors (HER2-enriched [HER2-E] and Basal-like) have higher expression of proliferation and…”
Get full text

HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trialResearch in context by Valentina Guarneri, Fara Bras..-Maristany, Maria Vittoria Dieci, Gaia Griguolo, Laia Par, Mercedes Mar.ín-Aguilera, Federica Miglietta, Michele Bottosso, Carlo Alberto Giorgi, Paula Blasco, Oleguer Castillo, Patricia Galv..n, Ana Vivancos, Patricia Villagrasa, Joel S. Parker, Charles M. Perou, PierFranco Conte, Aleix Prat

“…Background: HER2DX is a prognostic and predictive assay in early-stage HER2-positive breast cancer based on clinical features and the expression of 4 gene…”
Get full text

Abstract P4-02-30: Association between tumor infiltrating lymphocytes (TILs) and the HER2DX assay in early-stage of HER2-positive (HER2+) breast cancer by Sanfeliu, Esther, Brasó-Maristany, Fara, Dieci, Maria Vittoria, Marín-Aguilera, Mercedes, González-Farré, Blanca, Griguolo, Gaia, Pascual, Tomas, Galván, Patricia, Angelats, Laura, Castillo, Oleguer, Blasco, Paula, Sirenko, Valeria, Jares, Pedro, Puig-Butillé, Joan Antón, Paré, Laia, Martínez, Antonio, Llombart-Cussac, Antonio, Cortés, Javier, Vivancos, Ana, Villagrasa, Patricia, Parker, Joel S, Perou, Charles M, Prat, Aleix, Conte, PierFranco, Guarneri, Valentina

“…Background: The HER2DX assay is a genomic test in early-stage HER2-positive (HER2+) breast cancer that provides prognostic and predictive information. HER2DX…”
Get full text

Abstract P1-04-05: Independent validation of the HER2DX genomic test in HER2-positive breast cancer treated with neoadjuvant paclitaxel, trastuzumab and pertuzumab (THP): a correlative analysis from the DAPHNe phase II clinical trial by Waks, Adrienne, Ogayo, Esther R., Paré, Laia, Marín-Aguilera, Mercedes, Brasó-Maristany, Fara, Galván, Patricia, Castillo, Oleguer, Martínez-Sáez, Olga, Vivancos, Ana, Villagrasa, Patricia, Tarantino, Paolo, Desai, Neelam, Guerriero, Jennifer, Metzger, Otto, Tung, Nadine, Krop, Ian, Parker, Joel S, Perou, Charles M., Prat, Aleix, Winer, Eric, Tolaney, Sara, Mittendorf, Elizabeth A.

“…Background: HER2DX is a 27-gene prognostic (risk-score) and predictive (pathological complete response [pCR]-score) assay in early-stage HER2+ breast cancer…”
Get full text